You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHD
PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOMIMETIX JV LLC Topic: 102
Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: RAFT PHARMACEUTICALS LLC Topic: NINDS
PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SensoDX II, LLC Topic: NIDA
Abstract Opioid abuse disorder (OAD) affects 2.1 million of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortality. In addition to its enormous social impact, OAD carries a multi-billion-dollar price tag that includes $78.5 billion, specifically for health care and other costs related to prescription opioid abuse and misuse. Although effect ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Elimu Informatics, Inc. Topic: 172
PROJECT SUMMARY Treatment with convalescent plasma (CP) was recently approved by the FDA for seriously ill patients of COVID-19. There are many institutions and hospitals that have implemented CP programs, but they all face the challenge of finding sufficient and appropriate donors. The constraints of matching, imbalances in supply and demand, and privacy concerns pose several challenges to engage ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.SBC: Douleur Therapeutics Inc Topic: NINDS
Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's DiseaseSBC: Amprion, Inc. Topic: NIA
This proposal is for a phase I/II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluids, which could be used for the biochemical diagnosis of Alzheimer’s disease (AD) and related tauopathies. AD is the most common dementia in the elderly population and one of the leading causes of death in the developed wor ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Oncosynergy, Inc. Topic: 999
PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Cetya Therapeutics, Inc. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health